BAM
TGTX icon

Belpointe Asset Management’s TG Therapeutics TGTX Stock Holding History

Belpointe Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,750
Closed -$102K – 3104
2023
Q1 		$102K Buy
6,750
+4,654
+222% +$70.7K 0.01% 1299
2022
Q4 		$24.8K Buy
+2,096
New +$15.2K ﹤0.01% 2031
2018
Q4 		– Sell
-43,435
Closed -$243K – 629
2018
Q3 		$243K Buy
+43,435
New +$496K 0.04% 407

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Belpointe Asset Management's TGTX Position: Q2 2023 in Review

Belpointe Asset Management sold out of TG Therapeutics (TGTX) in Q2 2023, closing a stake of 6,750 shares — an estimated $102K sold.

Belpointe Asset Management first reported a position in TGTX in Q3 2018 and held it in 3 quarters. The position peaked at $243K in Q3 2018. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

  • Belpointe Asset Management reported no remaining TG Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 6,750 TG Therapeutics shares in Q2 2023, an estimated $102K.
  • Belpointe Asset Management first reported a position in TG Therapeutics in Q3 2018 and held it in 3 quarters.
  • Belpointe Asset Management's TG Therapeutics position peaked at $243K in Q3 2018.
  • 244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.